An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)

BACKGROUND: Pexmetinib (ARRY-614) is a dual inhibitor of p38 mitogen-activated protein kinase and Tie2 signaling pathways implicated in the pathogenesis of myelodysplastic syndromes. Previous clinical experience in a Phase I dose-escalation study of myelodysplastic syndrome patients using pexmetinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Wollenberg, Lance A, Corson, Donald T, Nugent, Courtney A, Peterson, Farran L, Ptaszynski, Ann M, Arrigo, Alisha, Mannila, Coralee G, Litwiler, Kevin S, Bell, Stacie J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598228/
https://www.ncbi.nlm.nih.gov/pubmed/26491375
http://dx.doi.org/10.2147/CPAA.S83871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598228/
https://www.ncbi.nlm.nih.gov/pubmed/26491375
http://dx.doi.org/10.2147/CPAA.S83871

Ejemplares similares